Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Washington for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Washington only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Washington (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Hakan Kaya (NPI 1255320974)

Field	Value
Entity Type	Individual
Organization	Hakan Kaya
Address	601 S Sherman St
City	Spokane
State	WA
ZIP	99202
Taxonomy	Medical Oncology Physician
NPI Enumerated	October 14, 2005

Payer Source	Total Paid
Medicare	$1.8M
Medicaid	$0

Key Findings

HAKAN KAYA is functionally a specialty oncology infusion practice based on the code mix and revenue drivers: high-volume biologic and chemotherapy drug codes (J9144, J2783, J0897, Q5119, J9041) dominate the ledger while E/M and infusion administration codes (99215, 96413, 96401, 96375) appear as supportive clinical visit and chemotherapy administration services. The presence of many HCPCS drug codes and infusion CPTs indicates the practice’s revenue is driven primarily by outpatient parenteral cancer therapies rather than by office visits or diagnostic imaging.

Medicare revenue is the sole recorded payer activity: total Medicare revenue is $1.8M while there is no Medicaid billing on file, so this provider effectively operates as a single-payer (Medicare) billing entity in the available data. Analysts should treat this profile as Medicare-focused for scale and utilization comparisons, with no statewide Medicaid activity to evaluate.

Revenue concentration is extreme: the precomputed top-3 Medicare codes account for 81.4% of this provider’s total Medicare revenue, showing the business is highly dependent on a very small set of treatments. In particular, J9144 alone accounts for $1.3M (71.5% of Medicare revenue), meaning one drug product dominates the revenue stream and operational throughput.

The provider’s national competitive standing is elevated for several specific drug codes: J9144 ranks #6 of 615 nationally and is labeled an extreme outlier, indicating volume for daratumumab administration is far above typical peers. Similarly, 99215 ranks in the 99th percentile (#1038 of 145531) and is also called an extreme outlier, suggesting unusually high use of high-complexity E/M visits relative to most clinicians. These high ranks point to HAKAN KAYA being a major national-volume administrator for selected oncology services.

A subset of codes show above-typical but not extreme volume, reflecting a focused product mix: J2783 (rasburicase) is listed as rank #1 of 1 with no peer comparison available, and J9041, J0897, Q5119, and 96401 fall in upper percentiles (68th–90th) or noted as notably above typical for 38222. This pattern suggests the provider treats a concentration of cancer indications that require both high-cost biologics and supportive agents, producing above-average utilization in several oncology-specific pharmaceuticals and procedures.

Clinical visit patterns support a high-acuity oncology practice: 635 claims for 99215 ($83.2K revenue) and 360 claims for 99214 indicate frequent high- and moderate-complexity established patient visits, consistent with ongoing chemotherapy management and complex decision making. These E/M volumes, combined with infusion and administration CPTs (96413, 96375, 96365), align with a workflow centered on recurrent infusion appointments and longitudinal cancer care.

Tenure is long: the provider’s NPI was enumerated on 2005-10-14 (~21 years ago), indicating an established practice presence in Spokane, WA. This longevity, together with concentrated high-volume drug billing, suggests sustained specialization in oncology services over many years.

From a payer or network perspective, the financial and operational risk is concentrated: relying on a few high-revenue drug codes (top three = 81.4% of Medicare revenue) exposes both payer and provider to utilization or pricing shifts for those agents. Contracting or utilization management discussions should therefore prioritize oversight of J9144 and the other top biologic administrations to understand clinical drivers and cost-control opportunities.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

44 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	35,640	$40	$1.3M
J2783	Injection, rasburicase, 0.5 mg	340	$280	$94.2K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	640	$130	$83.2K
J0897	Injection, denosumab, 1 mg	4,500	$20	$81K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	2,890	$20	$60.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	360	$90	$32K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	250	$110	$26.6K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	360	$60	$20.3K
J9041	Injection, bortezomib, 0.1 mg	4,520	$1	$18.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	220	$70	$14.6K

Showing 1–10 of 44

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 44 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Washington Distribution

Hakan Kaya — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Washington

Full comparison — all codes billed, vs. state median

44 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9144	1	10	6,480	$40	$357.9K
J2783	1	10	340	$280	$94.2K
J0897	31	150	1,800	$20	$57.9K
J3490	13	70	70	$50	$51.2K
Q5119	2	10	1,460	$20	$43.9K
96413	24	160	80	$110	$15K
99214	1,215	10,860	100	$80	$13.6K
74177	433	550	110	$80	$12.3K
J9041	1	10	3,080	$1	$11.2K
99233	1,113	2,420	60	$90	$10.4K

Showing 1–10 of 44

Related Providers

Other providers that share a Tax Identification Number (TIN) with Hakan Kaya, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
St. Joseph Hospital LLC	ID	General Acute Care Hospital	$0	$4.7M
Cancer Care Northwest Centers P S	WA	Hematology & Oncology Physician	$0	$3M
Danko Martincic	ID	Hematology & Oncology Physician	$2.6M	$0
Columbia Surgical Specialists, Ps	WA	Ambulatory Surgical Clinic/Center	$891.1K	$1.2M
Vijay Narendran	FL	Hematology & Oncology Physician	$2M	$0
Saritha Thumma	WA	Hematology & Oncology Physician	$1.8M	$0
Christopher Lee	WA	Radiation Oncology Physician	$1.7M	$0
Elizabeth Gunderson	WA	Medical Oncology Physician	$1.6M	$0
Srivalli Gopaluni	WA	Hematology & Oncology Physician	$1.6M	$0
Wayne Lamoreaux	WA	Radiation Oncology Physician	$1.5M	$0

Nearby Providers

Other providers in the same ZIP code as Hakan Kaya, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Multicare Health System	WA	Internal Medicine Physician	$0	$46.6M
Frontier Behavioral Health	WA	Community/Behavioral Health Agency	$0	$34.3M
Dungarvin Washington Children's Services, LLC	WA	Developmental Disabilities Clinic/Center	$0	$21.3M
Community Health Association Of Spokane	WA	Federally Qualified Health Center (FQHC)	$0	$8.2M
Providence Health & Services- Washington	WA	Rehabilitation Hospital	$0	$8M
Compass Career Solutions LLC	WA	Developmentally Disabled Services Day Training Agency	$0	$7.7M
Inland Imaging LLC	WA	Diagnostic Radiology Physician	$0	$6.8M
Northwest Autism Center	WA	Community/Behavioral Health Agency	$0	$5.9M
Northwest Pediatric Ophthalmology	WA	Ophthalmology Physician	$0	$4.2M
Inland Northwest Renal Care Group, LLC	WA	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$4.1M

Hakan Kaya — Billing Profile & Reimbursement Data

Sign up for Hakan Kaya — Billing Profile & Reimbursement Data policy alerts

Hakan Kaya — Billing Profile & Reimbursement Data

Sign up for Hakan Kaya — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References